Docoh
Loading...

LPCN Lipocine

Filed: 9 Nov 21, 8:00am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

November 9, 2021

 

 

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-36357

 

Delaware 99-0370688

(State or other jurisdiction

of incorporation)

 

(IRS Employer

Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01Other Events

 

Additionally, the Company is presenting data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 on November 12-15, 2021. The Company’s materials to be included are filed as Exhibits 99.1, 99.2 and 99.3.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are filed with this report:

 

Exhibit No. Description
   

99.1

 

Poster entitled “LPCN 1144 Therapy Demonstrates Histologic Benefits In The Phase 2 LiFT Study in Non-Alcoholic Steatohepatitis (NASH) Subjects”

   

99.2

 

Poster entitled “Safety And Tolerability Of LPCN 1144 Treatment In Biopsy Confirmed NASH Subjects In The Phase 2 LiFT Study”

   

99.3

 

Poster entitled “LPCN 1144 Improves Body Composition In Biopsy-Confirmed NASH Patients”

   

104

 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   LIPOCINE INC.
     
Date:November 9, 2021 By:/s/ Mahesh V. Patel
    Mahesh V. Patel
    President and Chief Executive Officer